Skip to main content
Clinical Trials/NL-OMON38231
NL-OMON38231
Recruiting
Not Applicable

Study on Working Memory in Adolescents with Autism in the Netherlands (amendment regarding an extension using fMRI) - SWAA

Epilepsiecentrum Kempenhaeghe0 sites276 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
High functioning Autism
Sponsor
Epilepsiecentrum Kempenhaeghe
Enrollment
276
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Sponsor
Epilepsiecentrum Kempenhaeghe

Eligibility Criteria

Inclusion Criteria

  • For adolescents with HFA:
  • \- Age of 12 to 16 years.
  • \- Autism disorder or Asperger disorder diagnosis made conform the diagnosis criteria as formulated in the DSM\-IV.
  • \- A signed informed consent (IC) from the adolescent and the parent/ caregiver.
  • \- A high average intelligence conform a HAVO/VWO education level.;For normal control adolescents:;\- Age of 12 to 16 years
  • \- A signed IC from the adolescent and the parent/ caregiver.
  • \- A high average intelligence conform a HAVO/VWO education level.

Exclusion Criteria

  • For adolescents with HFA:
  • \- A diagnosis for other (co\-morbid) psychological disorders or psychiatric diseases as formulated in the DSM\-IV, such as: attention\-deficit and disruptive behaviour disorders, anxiety disorders and mood disorders.
  • \- Appearance of additional variables that can influence cognitive functioning such as pathology of the Central Nervous System (CNS), significant hearing impairment, and medicinal treatment for epilepsy.
  • \- Use of Methylphenidate. In consultation with the responsible doctor, parent/caregiver and adolescent are asked if they are willing to not take the medicine on the day of the neuropsychological assessment. If all agree, the adolescent may participate in the study.
  • \- Inability to speak/understand the Dutch language.
  • \- Vision less than \+4\.5D or \- 4\.5D.
  • Claustrophobia.
  • Metal implants or other contraindication for MRI.;For normal control adolescents:
  • \- A diagnosis for a psychological disorder or psychiatric disease as formulated in the DSM\-IV, such as: pervasive developmental disorders, attention\-deficit and disruptive behaviour disorders, separation anxiety disorders, selective mutism, reactive attachment disorder of infancy or early childhood, anxiety disorders and mood disorders.
  • \- Appearance of additional variables that can influence cognitive functioning such as pathology of the CNS, significant hearing impairment, and medicinal treatment for epilepsy.

Outcomes

Primary Outcomes

Not specified

Similar Trials